TAK – Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company LTAK
$12.92Name : Takeda Pharmaceutical Company L
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $41,195,937,792.00
EPSttm : 0.59
Takeda Pharmaceutical Company L
$12.92
1.00%$0.13Float Short %
0.15
Margin Of Safety %
21
Put/Call OI Ratio
0.17
EPS Next Q Diff
-0.44
EPS Last/This Y
-0.29
EPS This/Next Y
Price
12.94
Target Price
15.25
Analyst Recom
2.2
Performance Q
-8.24
Relative Volume
0.83
Beta
0.55
Ticker: TAK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | TAK | 13 | 0.17 | 999.99 | 2110 |
| 2024-12-20 | TAK | 13.1 | 0.17 | 2.50 | 2111 |
| 2024-12-23 | TAK | 13.18 | 0.17 | 0.86 | 2061 |
| 2024-12-24 | TAK | 13.17 | 0.21 | 999.99 | 2200 |
| 2024-12-26 | TAK | 13.15 | 0.21 | 999.99 | 2200 |
| 2024-12-27 | TAK | 13.29 | 0.21 | 0.00 | 2203 |
| 2024-12-30 | TAK | 13.18 | 0.20 | 0.00 | 2271 |
| 2024-12-31 | TAK | 13.25 | 0.20 | 0.18 | 2274 |
| 2025-01-02 | TAK | 13.24 | 0.20 | 0.18 | 2274 |
| 2025-01-03 | TAK | 13.27 | 0.21 | 0.00 | 2289 |
| 2025-01-06 | TAK | 13.31 | 0.20 | 0.47 | 2300 |
| 2025-01-07 | TAK | 13.35 | 0.21 | 0.18 | 2343 |
| 2025-01-08 | TAK | 13.26 | 0.21 | 0.17 | 2351 |
| 2025-01-09 | TAK | 13.24 | 0.21 | 0.17 | 2351 |
| 2025-01-10 | TAK | 12.96 | 0.21 | 0.14 | 2351 |
| 2025-01-13 | TAK | 12.99 | 0.21 | 0.00 | 2496 |
| 2025-01-14 | TAK | 13.06 | 0.17 | 0.09 | 2998 |
| 2025-01-15 | TAK | 13.12 | 0.17 | 0.00 | 3002 |
| 2025-01-16 | TAK | 13.05 | 0.16 | 0.13 | 3015 |
| 2025-01-17 | TAK | 12.93 | 0.17 | 1.50 | 3018 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | TAK | 13.01 | - | -2.6 | 0.00 |
| 2024-12-20 | TAK | 13.10 | - | 9.7 | 0.00 |
| 2024-12-23 | TAK | 13.17 | - | 14.5 | 0.00 |
| 2024-12-24 | TAK | 13.17 | - | 6.3 | 0.00 |
| 2024-12-26 | TAK | 13.14 | - | 7.0 | 0.00 |
| 2024-12-27 | TAK | 13.28 | - | 16.1 | 0.00 |
| 2024-12-30 | TAK | 13.18 | - | -35.1 | 0.00 |
| 2024-12-31 | TAK | 13.24 | - | -18.3 | 0.00 |
| 2025-01-02 | TAK | 13.25 | - | -17.7 | 0.00 |
| 2025-01-03 | TAK | 13.27 | - | -15.2 | 0.00 |
| 2025-01-06 | TAK | 13.30 | - | 124.5 | 0.00 |
| 2025-01-07 | TAK | 13.35 | - | 130.1 | 0.00 |
| 2025-01-08 | TAK | 13.24 | - | 104.5 | 0.00 |
| 2025-01-09 | TAK | 13.24 | - | 110.5 | 0.00 |
| 2025-01-10 | TAK | 12.97 | - | 75.7 | 0.00 |
| 2025-01-13 | TAK | 12.99 | - | 100.9 | 0.00 |
| 2025-01-14 | TAK | 13.06 | - | 109.8 | 0.00 |
| 2025-01-15 | TAK | 13.10 | - | 114.9 | 0.00 |
| 2025-01-16 | TAK | 13.05 | - | 117.1 | 0.00 |
| 2025-01-17 | TAK | 12.94 | - | 126.2 | 0.00 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | TAK | 0.00 | 0.91 | 0.16 |
| 2024-12-20 | TAK | 0.00 | 0.91 | 0.16 |
| 2024-12-23 | TAK | 0.00 | 1.03 | 0.16 |
| 2024-12-24 | TAK | 0.00 | 1.03 | 0.16 |
| 2024-12-26 | TAK | 0.00 | 1.03 | 0.14 |
| 2024-12-27 | TAK | 0.00 | 1.03 | 0.14 |
| 2024-12-30 | TAK | 0.00 | -1.38 | 0.14 |
| 2024-12-31 | TAK | 0.00 | -1.38 | 0.14 |
| 2025-01-02 | TAK | 0.00 | -1.38 | 0.14 |
| 2025-01-03 | TAK | 0.00 | -1.38 | 0.14 |
| 2025-01-06 | TAK | 0.00 | -1.39 | 0.14 |
| 2025-01-07 | TAK | 0.00 | -1.39 | 0.14 |
| 2025-01-08 | TAK | 0.00 | -1.39 | 0.14 |
| 2025-01-09 | TAK | 0.00 | -1.39 | 0.14 |
| 2025-01-10 | TAK | 0.00 | -1.39 | 0.14 |
| 2025-01-13 | TAK | 0.00 | -0.44 | 0.15 |
| 2025-01-14 | TAK | 0.00 | -0.44 | 0.15 |
| 2025-01-15 | TAK | 0.00 | -0.44 | 0.15 |
| 2025-01-16 | TAK | 0.00 | -0.44 | 0.15 |
| 2025-01-17 | TAK | 0.00 | -0.44 | 0.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.44
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-0.44
Beta
0.55
Average Sales Estimate Current Quarter
1131610
Average Sales Estimate Next Quarter
1043860
Fair Value
15.68
Quality Score
70
Growth Score
62
Sentiment Score
19
Actual DrawDown %
36.6
Max Drawdown 5-Year %
-35.9
Target Price
15.25
P/E
21.43
Forward P/E
29.13
PEG
0.61
P/S
1.36
P/B
0.85
P/Free Cash Flow
10.07
EPS
0.6
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
6.36
Relative Volume
0.83
Return on Equity vs Sector %
-14.9
Return on Equity vs Industry %
-4.5
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
126.2
Takeda Pharmaceutical Company LSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 49281
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
stock quote shares TAK – Takeda Pharmaceutical Company Limited Stock Price stock today
news today TAK – Takeda Pharmaceutical Company Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TAK – Takeda Pharmaceutical Company Limited yahoo finance google finance
stock history TAK – Takeda Pharmaceutical Company Limited invest stock market
stock prices TAK premarket after hours
ticker TAK fair value insiders trading